Literature DB >> 22370911

Antithrombotic activity of protein S infused without activated protein C in a baboon thrombosis model.

M J Heeb1, U Marzec, A Gruber, S R Hanson.   

Abstract

Protein S (ProS) is an essential plasma protein that enhances the anticoagulant activity of activated protein C (APC). In vitro , purified native human Zn2+-containing ProS also exerts direct anticoagulant activity by inhibiting prothrombinase and extrinsic FXase activities independently of APC. We investigated antithrombotic effects of ProS infused without APC in a baboon shunt model of thrombogenesis that employs a device consisting of arterial and venous shear flow segments. In in vitro experiments, the Zn2+-containing human ProS used for the studies displayed >10-fold higher prothrombinase inhibitory activity and anticoagulant activity in tissue factor-stimulated plasma, and four-fold higher inhibition of the intrinsic pathway than the Zn2+-deficient ProS used. In the thrombosis model, ProS (33 μg/minute for 1 hour) or saline was infused locally; platelet and fibrin deposition in the shunt were measured over 2 hours. During experiments performed at 50 ml/minute blood flow, Zn2+-containing ProS inhibited platelet deposition 73-96% in arterial-type flow segments and 90-99% in venous-type flow segments; Zn2+-deficient ProS inhibited platelet deposition 52% in arterial-type flow segments and 65-73% in venous-type flow segments. At 100 ml/min blood flow rate, Zn2+-containing ProS inhibited platelet deposition by 39% and 73% in the respective segments; Zn2+-deficient ProS inhibited platelet deposition by 5% and 0% in the respective segments. Zn2+-containing ProS suppressed fibrin deposition by 67-90%. Systemic APC-independent ProS activity was significantly increased and thrombin-antithrombin complex levels were significantly decreased after infusion of ProS. Thus, infused human Zn2+-containing ProS is antithrombotic in primates, and may have therapeutic potential even in protein C-deficient human patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22370911      PMCID: PMC3319843          DOI: 10.1160/TH11-10-0699

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  28 in total

1.  Severe sepsis--a new treatment with both anticoagulant and antiinflammatory properties.

Authors:  M A Matthay
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

2.  Neonatal purpura fulminans associated with homozygous protein S deficiency.

Authors:  C Mahasandana; V Suvatte; R A Marlar; M J Manco-Johnson; L J Jacobson; W E Hathaway
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

3.  Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model.

Authors:  A Gruber; J H Griffin; L A Harker; S R Hanson
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

4.  Expression of the vitamin K-dependent proteins GAS6 and protein S and the TAM receptor tyrosine kinases in human atherosclerotic carotid plaques.

Authors:  B Hurtado; X Muñoz; P Recarte-Pelz; N García; A Luque; J Krupinski; N Sala; P García de Frutos
Journal:  Thromb Haemost       Date:  2011-03-08       Impact factor: 5.249

5.  Gamma-carboxylated isoforms of recombinant human protein S with different biologic properties.

Authors:  B W Grinnell; J D Walls; C Marks; A L Glasebrook; D T Berg; S B Yan; N U Bang
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

6.  Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.

Authors:  S R Hanson; J H Griffin; L A Harker; A B Kelly; C T Esmon; A Gruber
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

7.  Plasma protein S deficiency in familial thrombotic disease.

Authors:  H P Schwarz; M Fischer; P Hopmeier; M A Batard; J H Griffin
Journal:  Blood       Date:  1984-12       Impact factor: 22.113

8.  The C4b-binding protein-protein S complex inhibits the phagocytosis of apoptotic cells.

Authors:  Lena Kask; Leendert A Trouw; Björn Dahlbäck; Anna M Blom
Journal:  J Biol Chem       Date:  2004-04-19       Impact factor: 5.157

9.  Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C.

Authors:  M J Heeb; R M Mesters; G Tans; J Rosing; J H Griffin
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

10.  Regulation of activated protein C by a new protein. A possible function for bovine protein S.

Authors:  F J Walker
Journal:  J Biol Chem       Date:  1980-06-25       Impact factor: 5.157

View more
  5 in total

1.  The Journey of Protein S from an Anticoagulant to a Signaling Molecule.

Authors:  V S Pilli; William Plautz; Rinku Majumder
Journal:  JSM Biochem Mol Biol       Date:  2016-08-08

2.  Platelet protein S directly inhibits procoagulant activity on platelets and microparticles.

Authors:  Fabian Stavenuiter; Nicole F Davis; Erning Duan; Andrew J Gale; Mary J Heeb
Journal:  Thromb Haemost       Date:  2012-12-13       Impact factor: 5.249

3.  Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation.

Authors:  Mary J Heeb; Rolf M Mesters; José A Fernández; Tilman M Hackeng; Ryon K Nakasone; John H Griffin
Journal:  Thromb Haemost       Date:  2013-05-23       Impact factor: 5.249

4.  Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis.

Authors:  William E Plautz; Vijaya Satish Sekhar Pilli; Brian C Cooley; Rima Chattopadhyay; Pamela R Westmark; Todd Getz; David Paul; Wolfgang Bergmeier; John P Sheehan; Rinku Majumder
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-02-01       Impact factor: 8.311

5.  Interspecies comparison of simultaneous thrombin and plasmin generation.

Authors:  Ivan D Tarandovskiy; Hye Kyung H Shin; Jin Hyen Baek; Elena Karnaukhova; Paul W Buehler
Journal:  Sci Rep       Date:  2020-03-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.